Despite the inspiring hope immunotherapy brings; currently, the success rate in curing cancer is around 20%. There is a massive challenge in turning unresponsive tumors into responsive ones.
We found that modulating nucleic acid metabolism to generate more pyrimidines over purines can promote the presentation of more immunogenic antigens and improve the response to immunotherapy. We aim to find novel and available metabolic modulators that can generate nucleotide imbalance and benefit cancer patients' response to therapy and outcomes.